Abstract：
UNASSIGNED: To evaluate the risk of recurrence of severe placenta-mediated pregnancy complications and compare the efficacy of two different anti-thrombotic regimens in women with a history of late fetal loss without thrombophilia.
UNASSIGNED: We performed a 10-year retrospective observational study (2008-2018) analyzing a cohort of 128 women who suffered from pregnancy fetal loss (>20 weeks of gestational age) with histological evidence of placental infarction. All the women tested negative for congenital and/or acquired thrombophilia. In their subsequent pregnancies, 55 received prophylaxis with acetylsalicylic acid (ASA) only and 73 received ASA plus low molecular weight heparin (LMWH).
UNASSIGNED: Overall, one-third of all pregnancies (31%) had adverse outcomes related to placental dysfunction: pre-term births (25% <37 weeks, 5.6% <34 weeks), newborns with birth weight <2500 g (17%), and newborns small for gestational age (5%). The prevalence of placental abruption, early and/or severe preeclampsia, and fetal loss >20 weeks were 6%, 5%, and 4% respectively. We found a risk reduction for combination therapy (ASA plus LMWH) compared with ASA alone for delivery <34 weeks (RR 0.11, 95% CI: 0.01-0.95 p = 0.045) and a trend for the prevention of early/severe preeclampsia (RR 0.14, 95% CI: 0.01-1.18, p = 0.0715), while no statistically significant difference was observed for composite outcomes (RR 0.51, 95%CI: 0.22-1.19, p = 0.1242). An absolute risk reduction of 5.31% was observed for the ASA plus LMWH group. Multivariate analysis confirmed a risk reduction for delivery <34 weeks (RR 0.32, 95% CI 0.16-0.96 p = 0.041).
UNASSIGNED: In our study population, the risk of recurrence of placenta-mediated pregnancy complications is substantial, even in the absence of maternal thrombophilic conditions. A reduction of the risk of delivery <34 weeks was detected in the ASA plus LMWH group.
UNASSIGNED: We performed a 10-year retrospective observational study (2008-2018) analyzing a cohort of 128 women who suffered from pregnancy fetal loss (>20 weeks of gestational age) with histological evidence of placental infarction. All the women tested negative for congenital and/or acquired thrombophilia. In their subsequent pregnancies, 55 received prophylaxis with acetylsalicylic acid (ASA) only and 73 received ASA plus low molecular weight heparin (LMWH).
UNASSIGNED: Overall, one-third of all pregnancies (31%) had adverse outcomes related to placental dysfunction: pre-term births (25% <37 weeks, 5.6% <34 weeks), newborns with birth weight <2500 g (17%), and newborns small for gestational age (5%). The prevalence of placental abruption, early and/or severe preeclampsia, and fetal loss >20 weeks were 6%, 5%, and 4% respectively. We found a risk reduction for combination therapy (ASA plus LMWH) compared with ASA alone for delivery <34 weeks (RR 0.11, 95% CI: 0.01-0.95 p = 0.045) and a trend for the prevention of early/severe preeclampsia (RR 0.14, 95% CI: 0.01-1.18, p = 0.0715), while no statistically significant difference was observed for composite outcomes (RR 0.51, 95%CI: 0.22-1.19, p = 0.1242). An absolute risk reduction of 5.31% was observed for the ASA plus LMWH group. Multivariate analysis confirmed a risk reduction for delivery <34 weeks (RR 0.32, 95% CI 0.16-0.96 p = 0.041).
UNASSIGNED: In our study population, the risk of recurrence of placenta-mediated pregnancy complications is substantial, even in the absence of maternal thrombophilic conditions. A reduction of the risk of delivery <34 weeks was detected in the ASA plus LMWH group.
摘要：
UNASSIGNED：评估严重胎盘介导的妊娠并发症的复发风险，并比较两种不同抗血栓治疗方案在有晚期胎儿丢失史但无血栓形成倾向的妇女中的疗效。
UNASSIGNED：我们进行了一项为期10年的回顾性观察性研究（2008-2018年），分析了128名妊娠胎儿丢失（胎龄>20周）的女性队列，并有胎盘梗塞的组织学证据。所有妇女的先天性和/或获得性血栓形成倾向检测均为阴性。在他们随后的怀孕中，55只接受了乙酰水杨酸（ASA）的预防，73只接受了ASA加低分子量肝素（LMWH）的预防。
未经评估：总的来说，三分之一的孕妇（31%）有与胎盘功能障碍相关的不良结局：早产（25%<37周，5.6%<34周)，出生体重<2500克（17%）的新生儿，和小于胎龄的新生儿(5%)。胎盘早剥的患病率,早期和/或重度子痫前期，胎儿丢失>20周为6%，5%,分别为4%。我们发现，联合治疗（ASA加LMWH）与单独的ASA相比，<34周（RR0.11，95％CI：0.01-0.95p=0.045）的风险降低，并且预防早期/重度先兆子痫的趋势（RR0.14，95％CI：0.01-1.18，p=0.0715），而复合结局无统计学差异(RR0.51,95CI:0.22-1.19,p=0.1242).ASA加LMWH组的绝对风险降低5.31%。多变量分析证实分娩<34周的风险降低(RR0.32,95%CI0.16-0.96p=0.041)。
未经证实：在我们的研究人群中，胎盘介导的妊娠并发症复发的风险很大，即使在没有母体血栓形成的情况下。在ASA加LMWH组中检测到<34周的分娩风险降低。
UNASSIGNED：我们进行了一项为期10年的回顾性观察性研究（2008-2018年），分析了128名妊娠胎儿丢失（胎龄>20周）的女性队列，并有胎盘梗塞的组织学证据。
未经评估：总的来说，
未经证实：在我们的研究人群中，
